Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors

(2023) Tanja Mesti et al.   Biomedicines

Cutaneous melanoma

(2023) Georgina V Long et al.   LANCET

The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy

(2022) L. Susok et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

(2022) Claus Garbe et al.   EUROPEAN JOURNAL OF CANCER

The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy

(2021) Giovanni Fucà et al.   Targeted Oncology

Expression of Mismatch Repair Proteins in Merkel Cell Carcinoma

(2021) Thilo Gambichler et al.   Cancers

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis

(2018) Rita Pinto-Proença et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival

(2016) Elisabetta Panza et al.   Oncotarget

COX-2 expression in malignant melanoma: a novel prognostic marker?

(2009) Maria R. Becker et al.   MELANOMA RESEARCH